

CLAIMS

1. Use of a composition in the manufacture of a medicament for treating cancer wherein the composition comprises an antibody that binds to CD47 or an antigen-binding fragment thereof comprising a variable heavy chain (VH) region and a variable light chain (VL) region combination selected from the group consisting of:

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 33; a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 34;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 35;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 36;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 39;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 7, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 43;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 42;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 43;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 44;

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 11, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 47; and

a VH region comprising a sequence having 2-12 amino acid modifications in the framework region of SEQ ID NO: 28, and a VL region comprising a sequence having 1-11 amino acid modifications in the framework region of SEQ ID NO: 35.

2. The use according to claim 1, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from the group consisting of IgG1 isotype, IgG2 isotype, IgG3 isotype, and IgG4 isotype.
3. The use according to any one of claims 1 to 2, wherein the antibody or antigen-binding fragment thereof is an IgG isotype selected from IgG4P and IgG4PE.
4. The use according to any one of claims 1 to 3, wherein the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.
5. The use according to any one of claims 1 to 4, wherein the antibody or antigen-binding fragment thereof is to be administered to the subject at a dose of 0.3, 1, 2, 4, 8, 15, or 20 mg/kg.
6. The use according to any one of claims 1 to 5, wherein the rituximab is to be administered to the subject at a dose of 300, 325, 350, 375, 400, 425, 450, or 500 mg/m².

7. The use according to any one of claims 1 to 6, wherein the composition further comprises another anti-cancer agent.
8. The use according to any one of claims 1 to 7, wherein the cancer is a hematological cancer.
9. The use according to claim 8, wherein the hematological cancer is multiple myeloma, non-Hodgkin's lymphoma, or acute myeloid leukemia (AML).
10. The use according to claim 9, wherein the hematological cancer is non-Hodgkin's lymphoma.
11. The use according to claim 10, wherein the non-Hodgkin's lymphoma is CD20 positive.
12. The use according to claim 10, wherein the non-Hodgkin's lymphoma is relapsed or refractory.
13. The use according to claim 10, wherein the subject has previously been treated with rituximab.
14. The use according to any one of claims 1 to 9, wherein the composition does not comprise a proteasome inhibitor.
15. The use according to claim 14, wherein the proteasome inhibitor is bortezomib.
16. The use according to any one of claims 1 to 15, wherein the composition does not comprise methotrexate.